These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 16631684

  • 1. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
    Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D.
    Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW, Liu CJ, Lai MY, Lee PH, Tsai MK, Wang SS, Lai MK, Kao JH.
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [Abstract] [Full Text] [Related]

  • 6. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R, Amada N, Sato T, Orii T, Kikuchi H, Haga I, Ohashi Y, Okazaki H.
    Clin Transplant; 2006 Sep; 20(3):351-8. PubMed ID: 16824154
    [Abstract] [Full Text] [Related]

  • 7. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK.
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [Abstract] [Full Text] [Related]

  • 8. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW.
    Clin Transplant; 2006 Nov; 20(3):369-73. PubMed ID: 16824156
    [Abstract] [Full Text] [Related]

  • 9. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, Zuckerman M, Mufti GJ.
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [Abstract] [Full Text] [Related]

  • 10. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G, Gruttadauria S, Volpes R, D'Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM, Gridelli B.
    Clin Transplant; 2011 Dec; 25(1):E77-81. PubMed ID: 21039887
    [Abstract] [Full Text] [Related]

  • 11. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R.
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [Abstract] [Full Text] [Related]

  • 12. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen.
    Filik L, Karakayali H, Moray G, Dalgiç A, Emiroğlu R, Ozdemir N, Colak T, Gür G, Yilmaz U, Haberal M.
    Transplant Proc; 2006 Mar; 38(2):496-8. PubMed ID: 16549158
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [Abstract] [Full Text] [Related]

  • 17. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
    Lo CM, Liu CL, Chan SC, Lau GK, Fan ST.
    J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
    [Abstract] [Full Text] [Related]

  • 18. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.